new england journal of medicine tirzepatide In the SUMMIT trial, researchers examined cardiovascular outcomes treatment with in patients with heart failure with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: https://t.co/8joe2mst3e New England Journal Of Medicine

In addition to its role in diabetes management, liraglutide (Saxenda) is approved for use in promoting weight loss in certain adults and adolescents who are obese or overweight with weight-related medical problems

The payoff of these long-term changes is significant, including a lower risk of chronic disease, improved overall health, weight loss that can be maintained without medication, and better physical and mental well-being

The creatures venom, which evolved to incapacitate small prey and discourage predators, now circulates in millions of human patients in the form of synthetic exenatide and its descendants

10.1056/NEJMoa2032183 67 WitkowskiM.WilkinsonL.WebbN.WeidsA.GlahD.VrazicH